Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Designating an Orphan Product: Drugs and Biological Products

Designating an Orphan Product: Drugs and Biological Products

                        Orphan Drug Designation Request Form
          Orphan Drug Act - Relevant Excerpts
          Frequently Asked Questions (FAQ) About Designating an Orphan Product
          Orphan Drug Designation: Disease Considerations
          Clinical Superiority Findings
          Instructions for Searchable Designation Database
          Public Identification of Orphan Drug Designation
          Improving the Prevention, Diagnosis, and Treatment of Rare and Neglected Diseases; FDA Report to Congress
          Contact Us Home
          For Industry
          Medical products for rare diseases and conditions
          Designating an Orphan Product: Drugs and Biological Products
          Orphan Drug Designation: Disease ConsiderationsDesignating an Orphan Product: Drugs and Biological Products Orphan Drug Designation: Disease Considerations
  
  	
    Share
    Post
    Linkedin

    Email
    PrintWhen reviewing a request for orphan drug designation, FDA considers the mechanism of action of the drug to determine what distinct disease or condition the drug is intended to treat, diagnose or prevent.Whether a given medical condition constitutes a distinct disease or condition for the purpose of orphan-drug designation depends on a number of factors, assessed cumulatively, including: Pathogenesis of the disease or condition; course of the disease or condition; prognosis of the disease or condition; and resistance to treatment. These factors are analyzed in the context of the specific drug for which designation is requested. [1]

Sickle Cell Disease - feature 2
During the course of reviewing a request for orphan drug designation, equipped with the most current scientific literature about a particular disease or condition, FDA may come to a new understanding about the nature of that disease or condition. Below is a list of some diseases or conditions for which FDA’s views on how it categorizes or otherwise understands the disease or condition has evolved. This is not a comprehensive list of orphan disease determinations, but reflective of some of the more common questions we receive. FDA will update this list as appropriate when it makes orphan drug designation determinations that change how we approach the disease or condition in question. For a complete list of orphan drug designations and approvals see the searchable Orphan Products Designation Database.

Disease or Condition at issue
			For the purpose of Orphan Drug Designation, what FDA considers the disease or condition to be:Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
			FDA considers ovarian cancer, fallopian tube cancer, and primary peritoneal cancer to be one distinct disease or condition.Metastatic Brain Cancer
			FDA considers any primary tumor type that has metastasized to the brain to be its own distinct disease or condition. For example, breast cancer that has metastasized to the brain is a distinct disease from breast cancer.Pulmonary Hypertension
			FDA recognizes the five WHO classifications of pulmonary hypertension as distinct diseases or conditions.Scleroderma
			FDA considers systemic sclerosis to be a different disease or condition than localized scleroderma.Lymphoma
			FDA recognizes the WHO classifications of lymphoma as distinct diseases or conditions.Familial Adenomatous Polyposis
			FDA recognizes Familial Adenomatous Polyposis as a distinct disease or condition from sporadic adenomatous polypsMedication-induced Dyskinesia in Parkinson’s Disease
			FDA recognizes Medication-induced Dyskinesia in Parkinson’s Disease (PD) as the disease or condition. Levodopa-induced dyskinesia in PD is considered to be a subset of Medication induced Dyskinesia in PD.

[1] See FDA, Orphan Drug Regulations, Final Rule, 78 Fed. Reg. 35117, 35120 (June 12, 2013).

                                                                                  Content current as of:
      03/09/2018Designating an Orphan Product: Drugs and Biological Products

          
                        Orphan Drug Designation Request Form
          Orphan Drug Act - Relevant Excerpts
          Frequently Asked Questions (FAQ) About Designating an Orphan Product
          Orphan Drug Designation: Disease Considerations
          Clinical Superiority Findings
          Instructions for Searchable Designation Database
          Public Identification of Orphan Drug Designation
          Improving the Prevention, Diagnosis, and Treatment of Rare and Neglected Diseases; FDA Report to Congress
          Contact Us
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop